Pegaptanib sodium for ocular vascular disease.

Article Details

Citation

Copy to clipboard

Shukla D, Namperumalsamy P, Goldbaum M, Cunningham ET Jr

Pegaptanib sodium for ocular vascular disease.

Indian J Ophthalmol. 2007 Nov-Dec;55(6):427-30. doi: 10.4103/0301-4738.36476.

PubMed ID

17951898 [ View in PubMed

]

Abstract

Pegaptanib sodium (Macugen) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF) 165 , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF 121 . After more than 10 years in development and preclinical study, pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration. Its excellent ocular and systemic safety profile has also been confirmed in patients receiving up to three years of therapy. Early, well-controlled studies further suggest that pegaptanib may provide therapeutic benefit for patients with diabetic macular edema, proliferative diabetic retinopathy and retinal vein occlusion. Notably, pegaptanib was the first available aptamer approved for therapeutic use in humans and the first VEGF inhibitor available for the treatment of ocular vascular diseases.

DrugBank Data that Cites this Article

Drugs

Pegaptanib

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pegaptanib	Vascular endothelial growth factor A	Protein	Humans	Yes	Antagonist	Details